» Articles » PMID: 24452334

Glycogen Accumulation Underlies Neurodegeneration and Autophagy Impairment in Lafora Disease

Overview
Journal Hum Mol Genet
Date 2014 Jan 24
PMID 24452334
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Lafora disease is a fatal neurodegenerative condition characterized by the accumulation of abnormal glycogen inclusions known as Lafora bodies. It is an autosomal recessive disorder caused by mutations in either the laforin or malin gene. To study whether glycogen is primarily responsible for the neurodegeneration in Lafora disease, we generated malin knockout mice with impaired (totally or partially) glycogen synthesis. These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model. Interestingly, the autophagy impairment that has been described in malin knockout animals was also rescued in this double knockout model. Conversely, two other mouse models in which glycogen is over-accumulated in the brain independently of the lack of malin showed impairment in autophagy. Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy. These results identify the regulation of glycogen synthesis as a key target for the treatment of Lafora disease.

Citing Articles

Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity.

Gumusgoz E, Kasiri S, Youssef I, Verma M, Chopra R, Villarreal Acha D Gene Ther. 2025; .

PMID: 39893321 DOI: 10.1038/s41434-025-00517-w.


Glycogen homeostasis and mitochondrial DNA expression require motor neuron to muscle TGF-β/Activin signaling in Drosophila.

Bretscher H, OConnor M iScience. 2025; 28(1):111611.

PMID: 39850360 PMC: 11754121. DOI: 10.1016/j.isci.2024.111611.


Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease.

Nitschke S, Montalbano A, Whiting M, Smith B, Mukherjee-Roy N, Marchioni C EMBO J. 2025; 44(5):1379-1413.

PMID: 39806098 PMC: 11876434. DOI: 10.1038/s44318-024-00339-3.


Dapagliflozin ameliorates Lafora disease phenotype in a zebrafish model.

Della Vecchia S, Imbrici P, Liantonio A, Naef V, Damiani D, Licitra R Biomed Pharmacother. 2025; 183:117800.

PMID: 39753095 PMC: 11794196. DOI: 10.1016/j.biopha.2024.117800.


VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial.

Muccioli L, Vignatelli L, Tappata M, Mazzone S, Zenesini C, Armstrong D BMJ Open. 2024; 14(10):e085062.

PMID: 39424378 PMC: 11492954. DOI: 10.1136/bmjopen-2024-085062.